External validation of alk and ros1 fusions detected using an oncomine comprehensive assay

Background/Aim: This study aimed to assess the yield of an Oncomine comprehensive assay v3 (OCAv3)-based next-generation sequencing (NGS) analysis for detecting anaplastic lymphoma kinase (ALK) and c-ros oncogene 1 (ROS1) fusions in non-small cell lung cancer (NSCLC).Patients and Methods: NGS data from 85 NSCLC cases were reviewed.ALK and ROS1 fusion status was compared to conventional tests.Results: ALK or ROS1 fusion reads were detected in 17 NSCLC cases.Results in 10 NSCLC cases showed concordance with conventional tests, high-count fusion reads, a lack of mutually exclusive mutations of ALK or ROS1, and frequent signet-ring cell component.Seven NSCLC cases showing discordant results exhibited low to intermediate fusion read counts and mutations mutually exclusive from ALK or ROS1.Conclusion: Cases showing high-count fusion reads in OCAv3-based NGS have a strong possibility of carrying ALK or ROS1 fusion.Cases with low-to intermediate-count fusion reads should be interpreted with caution and may require additional confirmative tests.